Join to View Full Profile
5841 S. MARYLANDM/C 2115Chicago, IL 60637
Phone+1 773-702-8412
Fax+1 773-834-0188
Dr. Riedell is on Doximity
As a Doximity member you'll join over two million verified healthcare professionals in a private, secure network.
- Gain access to free telehealth tools, such as our “call shielding” and one-way patient texting.
- Connect with colleagues in the same hospital or clinic.
- Read the latest clinical news, personalized to your specialty.
Summary
- Dr. Peter Riedell is an oncologist in Chicago, IL and is affiliated with University of Chicago Medical Center. He received his medical degree from University of Tennessee College of Medicine and has been in practice 7 years. He specializes in hematologic oncology and is experienced in non-Hodgkin lymphoma, Hodgkin lymphoma, stem cell transplantation, and chimeric antigen receptor (CAR) T-cell therapy.
Education & Training
Washington University/B-JH/SLCH ConsortiumFellowship, Hematology and Medical Oncology, 2013 - 2016- Washington University/B-JH/SLCH ConsortiumResidency, Internal Medicine, 2010 - 2013
University of Tennessee Health Science Center College of MedicineClass of 2010
Certifications & Licensure
IL State Medical License 2016 - 2026
MO State Medical License 2012 - 2017
American Board of Internal Medicine Hematology- American Board of Internal Medicine Medical Oncology
Clinical Trials
- Phase I Study of Romidepsin, Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed/Refractory Aggressive Lymphomas Start of enrollment: 2015 Feb 04
- Ibrutinib Before and After Stem Cell Transplant in Treating Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma Start of enrollment: 2016 Oct 12
- Rituximab With or Without Stem Cell Transplant in Treating Patients With Minimal Residual Disease-Negative Mantle Cell Lymphoma in First Complete Remission Start of enrollment: 2017 Nov 27
- Join now to see all
Publications & Presentations
PubMed
- Two-stage CD8CAR T-cell differentiation in patients with large B-cell lymphoma.Guoshuai Cao, Yifei Hu, Tony Pan, Erting Tang, Nicholas Asby
Nature Communications. 2025-05-06 - A Phase I Study of Romidepsin in Combination With Gemcitabine, Oxaliplatin, and Dexamethasone in Patients With Relapsed or Refractory Aggressive Lymphomas Enriched for...Nicole Foley, Peter A Riedell, Nancy L Bartlett, Amanda F Cashen, Brad S Kahl
Clinical Lymphoma, Myeloma & Leukemia. 2025-05-01 - Lisocabtagene maraleucel for R/R LBCL in patients not intended for HSCT: final results of the phase 2 PILOT study.Alison Sehgal, Daanish Hoda, Peter A Riedell, Nilanjan Ghosh, Mehdi Hamadani
Blood Advances. 2025-04-30
Abstracts/Posters
- Romidepsin in Combination with Gemcitabine, Oxaliplatin, and Dexamethasone Shows Durable Responses in Aggressive LymphomasPeter A. Riedell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/7/2019
- Rapid Undetectable MRD (uMRD) Responses in Patients with Relapsed/Refractory (R/R) Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma (CLL/SLL) Treated with Lisoc...Peter A. Riedell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/8/2019
- A Phase 2, Open-Label, Multicenter Study Evaluating the Safety and Efficacy of Axicabtagene Ciloleucel in Combination with Either Rituximab or Lenalidomide in Patients...Peter A. Riedell, 61st Annual American Society of Hematology Meeting, Orlando, FL, 12/9/2019
- Join now to see all
Press Mentions
Axi-Cel vs Tisa-Cel in the Real World: Patterns of Use, Efficacy, and Safety in B-cell LymphomaApril 22nd, 2020
Experts Break down Latest CAR T-cell Advances in LymphomaJanuary 22nd, 2020
Triplet Notches Survival Win in Heavily Pretreated DLBCLJune 3rd, 2024- Join now to see all
Professional Memberships
- Member
- Member
- American Society of Transplantation and Cellular Therapy - ASTCTMember
External Links
- Jonas Center Cellular Therapy Symposiumhttps://www.jonascentersymposium.com
Viewing the full profile is available to verified healthcare professionals only.
Find your profile and take control of your online presence:
